Lipid-based systemic delivery of siRNA
Yu-Cheng Tseng1, Subho Mozumdar, Leaf Huang
1Division of Molecular Pharmaceutics, School of Pharmacy, University of North Carolina, Chapel Hill, NC 27599, USA.
Advanced Drug Delivery Reviews
|March 31, 2009
Summary
RNAi therapeutics offer versatile treatment for diseases by silencing genes. Overcoming delivery challenges, particularly endosome escape, is key for effective RNA interference (RNAi) therapy.
Area of Science:
- Biotechnology
- Molecular Biology
- Pharmacology
Background:
- RNA interference (RNAi) is a powerful gene-silencing mechanism with therapeutic potential.
- RNAi technology enables the downregulation of specific proteins for treating genetic diseases, viral infections, and cancer.
Purpose of the Study:
- To review the mechanism and therapeutic utility of RNAi.
- To discuss challenges and strategies for systemic small interfering RNA (siRNA) delivery.
- To highlight endosome escape as a critical step in RNAi therapy.
Main Methods:
- Review of RNAi machinery and its therapeutic applications.
- Categorization of siRNA delivery challenges into kinetic and physical barriers.
- Discussion of strategies to overcome delivery barriers, focusing on endosome escape.
Main Results:
- RNAi machinery is delicate and precise, posing delivery challenges.
- Systemic siRNA delivery faces kinetic and physical barriers.
- Endosome escape is a crucial hurdle for RNAi therapeutic efficacy.
Conclusions:
- Effective delivery systems are essential for RNAi-based therapies.
- Strategies focusing on endosome escape can enhance RNAi therapeutic outcomes.
- Lipid-based delivery systems show promise, with toxicity considerations.
Related Concept Videos
02:30siRNA - Small Interfering RNAs
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
02:15Experimental RNAi
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
01:23RNA Interference
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
01:24Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
02:30Small interfering RNAs (siRNA)
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...